Compugen Ltd. (CGEN)

Executive Summary / Key Takeaways

• Partnership-Driven Financial Inflection: Compugen transformed from a cash-burning R&D company to a profitable enterprise in 2025, generating $35.3 million in net profit on $72.8 million revenue—a 161% revenue surge driven by strategic monetization of its pipeline, fundamentally de-risking the investment case through non-dilutive funding.

• Four-Year Cash Runway with Zero Dilution Risk: The December 2025 AstraZeneca (AZN) royalty transaction delivered $65 million upfront, extending cash runway into 2029 while retaining majority royalty upside and increasing milestone potential to $195 million, creating a rare biotech that can reach multiple catalysts without shareholder dilution.

• Differentiated Technology in a Shifting IO Landscape: Compugen's Unigen computational platform has generated first-in-class assets like anti-PVRIG (COM701) and Fc-reduced anti-TIGIT (COM902) that offer potential safety and efficacy advantages as the broader TIGIT field faces clinical failures, positioning the company to benefit from evolving understanding of optimal antibody design.

• Multiple Near-Term Catalysts: The MAIA-ovarian trial interim analysis in Q1 2027 could establish COM701 as a maintenance monotherapy backbone, while 2026 Phase III data from Arcus (RCUS)/Gilead's (GILD) Fc-reduced TIGIT program may validate COM902's mechanism and unlock partnership opportunities for this wholly-owned asset.

• Valuation Disconnect with Peer Group: Trading at 0.91x EV/Revenue and 2.08x EV/EBITDA versus biotech peers averaging 6-11x revenue multiples, CGEN's partnership-validated platform and milestone-driven profitability appear underappreciated, though concentrated revenue from AstraZeneca (89% in 2025) and TIGIT field risks create meaningful execution asymmetry.

Setting the Scene: The Computational Immuno-Oncology Niche

Compugen Ltd., founded in Israel on February 10, 1993, operates as a clinical-stage therapeutic discovery company that has spent three decades building a differentiated position in the immuno-oncology market. Unlike traditional biotechs that rely on high-throughput screening, Compugen's core engine is Unigen, an AI/ML-powered computational discovery platform that identifies novel drug targets through predictive algorithms rather than empirical brute force. This approach fundamentally alters the economics of early-stage R&D—reducing both the time and capital required to generate clinically viable assets while creating a pipeline of first-in-class mechanisms that large pharma partners cannot easily replicate.

The company makes money through a partnership-centric model: it discovers and de-risks novel targets through preclinical development, then licenses them to pharmaceutical partners for clinical advancement and commercialization. This creates a capital-efficient flywheel where upfront payments, development milestones, and future royalties fund further platform investment without diluting shareholders. In 2025, this model generated $72.8 million in revenue, a 161% increase from 2024, with 89% coming from a single customer—AstraZeneca—through the monetization of rilvegostomig royalties.

Compugen sits at the intersection of two powerful industry trends: the $58.5 billion immuno-oncology market growing at 16.4% CAGR toward $229.6 billion by 2034, and the increasing application of AI/ML to drug discovery. The IO landscape is shifting dramatically as first-generation checkpoint inhibitors like PD-1/PD-L1 face diminishing returns and the TIGIT field experiences high-profile clinical failures from Roche (RHHBY), Merck (MRK), and Arcus/Gilead. This creates both risk and opportunity—while TIGIT skepticism has compressed valuations across the space, it also highlights the need for differentiated approaches like Compugen's Fc-reduced antibody design and novel targets like PVRIG that may synergize where PD-1 blockade alone fails.

Technology, Products, and Strategic Differentiation

Unigen Platform: The Computational Moat

Unigen is not merely a research tool but the foundation of Compugen's entire value proposition. Management emphasizes that this AI/machine-learning-based computational engine generated COM701, COM902, and GS-0321, validating the platform's ability to produce multiple clinical-stage assets from computer prediction. Each successful asset reduces the platform risk that plagues computational drug discovery companies and increases the probability that Unigen can continue delivering novel targets with commercial value. For investors, this translates to a non-linear upside scenario where early clinical success in one program validates the entire discovery engine, potentially unlocking premium valuations for a pipeline of undisclosed early-stage programs managed by Compugen's largest internal team.

The platform's economic impact is visible in the company's lean R&D spending. At $22.8 million in 2025—just 71% of operating expenses and down from $24.8 million in 2024—Compugen spends a fraction of what traditional biotechs invest to maintain similar-sized pipelines. This cost advantage becomes more pronounced when considering that 2025's R&D included increased expenses for the MAIA-ovarian trial while winding down prior studies. Unigen enables capital-efficient discovery that preserves cash runway while peers burn through hundreds of millions on empirical screening.

COM701: First-in-Class PVRIG in Ovarian Cancer

COM701 targets PVRIG, an immune checkpoint discovered computationally by Compugen in 2009, making it a potential first-in-class antibody in a validated but underserved pathway. The drug is being evaluated in the MAIA-ovarian trial as maintenance monotherapy for relapsed platinum-sensitive ovarian cancer—a setting where safety and tolerability are paramount because patients are asymptomatic and seeking to delay disease progression without compromising quality of life. This strategic positioning addresses a clear unmet need: existing maintenance options are limited, and the tolerability profile could drive adoption even if efficacy is modest.

Management has guided that a three-month improvement in median progression-free survival over placebo would be very clinically meaningful in this population. This specific threshold reflects realistic expectations in a maintenance setting where incremental gains translate to significant patient benefit and regulatory viability. The trial's blinded randomized design and platform structure allow for adaptive expansion if interim data is positive, potentially creating a monotherapy path-to-registration that avoids the cost and complexity of combination development. This represents a capital-efficient route to market that could generate early cash flows to fund broader development.

The tolerability data supports this thesis: pooled analysis showed no discontinuations due to adverse events, and management describes COM701 as "extremely well tolerated." In an era where IO toxicity concerns have derailed multiple TIGIT programs, this safety profile becomes a competitive differentiator that could enable combinations with chemotherapy or ADCs —modalities currently being evaluated in ovarian cancer. For the stock, positive Q1 2027 interim data would validate not just COM701 but the entire Unigen platform's ability to generate clinically viable first-in-class assets, likely triggering multiple expansion as investors price in pipeline depth.

COM902: The Fc-Reduced TIGIT Optionality

COM902 represents a strategic call option on the evolving understanding of TIGIT biology. As an Fc-reduced anti-TIGIT antibody, it is designed to preserve and reinvigorate effector T cells while avoiding depletion of peripheral Tregs—a mechanism management argues is superior to Fc-active designs that have failed in Phase III trials. Recent data from Roche's SKYSCRAPER trials showed high discontinuation rates (30% fewer doses administered) due to toxicity, which likely compromised efficacy outcomes. This suggests that safety isn't merely a side effect profile but directly impacts treatment intensity and clinical benefit.

Compugen is one of only two companies with Fc-reduced anti-TIGIT antibodies in clinical development, the other being Arcus/Gilead's domvanalimab. This exclusivity is significant because if Arcus/Gilead's Phase III data (expected in 2026) validates the Fc-reduced approach, COM902 would instantly become one of the few validated TIGIT assets available for partnership or acquisition. Management notes they do not plan to initiate new clinical trials due to recent TIGIT failures, but this conservative stance preserves capital while maintaining optionality. For investors, this creates a low-cost call option: minimal near-term investment with potential for significant value inflection if the class is validated.

The asset is fully owned by Compugen, meaning any future partnership would bring substantial upfront capital without revenue sharing. This represents potential non-dilutive funding that could extend the already-robust cash runway even further, while failure costs the company nothing in ongoing burn.

Rilvegostomig: The AstraZeneca Partnership Engine

Rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific incorporating Compugen's COM902, is the crown jewel of the partnership strategy. AstraZeneca is running 10 active Phase III trials across lung, gastric, and endometrial cancers with ambitions to replace PD-1/PD-L1 therapies and serve as the backbone for future combination treatment. This broad development diversifies indication risk and creates multiple shots at success, with AstraZeneca estimating non-risk-adjusted peak revenue exceeding $5 billion.

The December 2025 royalty monetization transaction is the single most important financial event for Compugen. By selling a portion of future royalties for $65 million upfront, management extended cash runway to 2029 while retaining majority royalty interest and increasing total milestones to $195 million. This transforms a distant, uncertain royalty stream into immediate non-dilutive capital that funds operations through multiple clinical catalysts. The implied discount rate on the royalty sale suggests management believes near-term capital has higher value than distant royalties, a rational decision for a company with multiple internal programs to advance.

For the stock, this transaction de-risks the investment case by eliminating near-term financing concerns while preserving upside. If rilvegostomig achieves even a fraction of AstraZeneca's peak sales estimate, retained royalties could generate tens of millions in annual cash flow starting in the early 2030s. The $25 million milestone at BLA acceptance provides a near-term catalyst, while the broader program validates Compugen's antibody design capabilities.

GS-0321: The Gilead-Validated IL-18 Pathway

GS-0321 (formerly COM503) targets IL-18 binding protein , a novel mechanism designed to free natural IL-18 activity in the tumor microenvironment while avoiding systemic cytokine toxicity. Gilead's $60 million upfront payment (January 2024) and $30 million IND milestone (Q3 2024) represent significant validation, with eligibility for up to $758 million in additional milestones plus tiered royalties. Gilead's investment transforms a preclinical hypothesis into a clinically validated program with a partner bearing all development costs, while Compugen retains upside through milestones and royalties.

Compugen is sponsoring the Phase I trial, which dosed its first patient in January 2025. This structure allows Compugen to maintain scientific leadership and build clinical expertise while Gilead funds the work, creating a low-cost option on a potential first-in-class asset. For investors, the Gilead partnership provides a second major validation of Unigen's capabilities beyond AstraZeneca, reducing platform risk and suggesting the pipeline can generate multiple partner-quality assets.

Financial Performance & Segment Dynamics: The Monetization Inflection

Compugen's 2025 financial results represent a fundamental inflection point that validates the partnership-centric business model. Revenue surged 161% to $72.8 million, driven by the $65 million AstraZeneca payment and Gilead milestones, while net income swung to a $35.3 million profit from a $14.2 million loss in 2024. This demonstrates that computational discovery platforms can generate near-term cash flows rather than requiring perpetual dilutive financing, a rarity in clinical-stage biotech that fundamentally alters the risk/reward profile.

The geographic revenue split—$65 million from the United Kingdom (AstraZeneca) and $7.8 million from the United States—reflects the partnership model's concentration risk but also its efficiency. A single deep relationship with a major pharma can fund years of operations, eliminating the need for expensive commercial infrastructure. The 89% customer concentration from AstraZeneca creates vulnerability, but also signals the quality of partner willing to commit $65 million upfront, suggesting robust confidence in the underlying asset.

Gross margin of 87.29% and operating margin of 83.23% reflect the milestone-heavy revenue mix. What matters is the underlying cost structure: R&D expenses declined 8% to $22.8 million despite advancing the MAIA-ovarian trial, demonstrating capital efficiency. General and administrative expenses fell 6% to $8.9 million through disciplined cost management. This lean operation preserves cash while maintaining scientific progress, extending runway without sacrificing pipeline advancement.

The balance sheet tells the most compelling story. Cash of $145.6 million at year-end 2025, up from $103.3 million, provides funding into 2029 assuming no further inflows. This four-year runway allows Compugen to reach the MAIA-ovarian interim analysis, potential Arcus/Gilead catalysts, and advance early-stage programs without dilutive financing—a critical advantage in a volatile biotech market where capital availability can disappear overnight. The minimal debt (0.03 debt-to-equity) provides strategic flexibility and eliminates financial distress risk.

Operating cash flow of $31.6 million and free cash flow of $31.3 million in 2025 compare to the $49.6 million provided in 2024 from larger Gilead payments. The company can generate positive cash flow even with fluctuating milestone timing, demonstrating operational sustainability rather than a one-time windfall.

Outlook, Management Guidance, and Execution Risk

Management's guidance frames 2026 as a year of continued focus on the early-stage pipeline, with the largest internal team working on undisclosed programs. This signals a strategic pivot from late-stage asset monetization back to discovery, using partnership capital to replenish the pipeline. The decision to withhold competitive details is prudent but creates uncertainty about the timing and quality of future assets. For investors, this represents a long-term call option: if Unigen continues generating partner-quality targets, the current valuation will prove conservative.

The MAIA-ovarian trial remains on track for Q1 2027 interim analysis, with all 28 sites now open across the U.S., Israel, and France. Management's guidance that a three-month PFS improvement would be clinically meaningful sets realistic expectations for a maintenance setting where incremental gains drive regulatory approval. The blinded randomized design allows for adaptive expansion if positive, creating a capital-efficient path to registration that could generate early revenues and validate monotherapy utility.

AstraZeneca's rilvegostomig program provides multiple near-term catalysts. With 10 active Phase III trials and anticipated Phase 1/2 data in 2026, investors will receive regular updates on the Fc-reduced TIGIT approach. Each positive readout reduces platform risk for Compugen and increases the probability of eventual royalty payments, while also validating COM902's design. The $25 million milestone at BLA acceptance provides a specific near-term capital infusion target.

The Arcus/Gilead Phase III data expected in 2026 represents a potential class-validation event for Fc-reduced TIGIT antibodies. Management explicitly states this could be a real catalyst for COM902. If domvanalimab succeeds, COM902's value would re-rate from a shelved asset to a validated, partnership-ready program, potentially generating significant upfront payments. The risk is asymmetric: limited downside from maintaining the status quo, substantial upside from class validation.

Gilead's GS-0321 Phase I trial, with first patient dosed in January 2025, will generate initial safety and activity data that could be reported at medical conferences. While Gilead controls disclosure timing, any positive signals would validate the IL-18BP mechanism and support the $758 million milestone potential. This represents a second major pipeline catalyst independent of the TIGIT/PVRIG programs.

Risks and Asymmetries: What Could Break the Thesis

The TIGIT field's recent failures represent the most significant external risk. Roche's SKYSCRAPER trials, Merck's KeyVibe studies, and Arcus/Gilead's STAR-221 discontinuation have created market skepticism about the entire pathway. Despite rilvegostomig's Fc-reduced design and AstraZeneca's extensive development program, a major Phase III failure could permanently impair TIGIT valuations and reduce COM902's partnership potential. Management acknowledges this risk but argues that Fc-active designs caused depletion of effector T cells and high discontinuation rates, while Fc-reduced antibodies preserve immune function. The asymmetry lies in whether the market will differentiate between designs or treat all TIGIT antibodies as tainted.

Customer concentration risk is immediate and material. With 89% of 2025 revenue from AstraZeneca, any deterioration in the partnership would devastate near-term cash flows. While the relationship appears strong, pharma partnerships can shift rapidly based on portfolio priorities. The $195 million in remaining milestones provides some visibility, but the royalty monetization means Compugen has traded long-term upside for near-term certainty, increasing dependence on AstraZeneca's continued development commitment.

Clinical trial execution risk centers on the MAIA-ovarian enrollment. While management reports all 28 sites are now open, the trial's adaptive design requires sufficient events to observe clinical activity. Any delay in the Q1 2027 interim analysis would push back potential partnership discussions and monotherapy registration plans, extending cash burn and compressing valuation multiples as investors question execution capability.

Platform risk remains despite validation. Management candidly states that Unigen is not yet fully proven clinically, and while three assets have reached clinical trials, the early-stage pipeline's undisclosed nature creates uncertainty about future productivity. If Unigen's success was coincidental rather than systematic, the company's ability to replenish the pipeline after current assets mature would be compromised, transforming Compugen from a platform company into a single-asset story.

Geopolitical risk is particularly relevant for an Israeli company. The ongoing conflict in the region and the February 2026 joint operation against Iran create operational disruption risk and could affect clinical trial sites in Israel. While management has maintained operations through prior conflicts, escalating regional instability could delay trials, impact talent retention, or create regulatory hurdles for international partnerships.

Valuation Context: Discounted Platform with Catalyst Optionality

At $2.20 per share, Compugen trades at a market capitalization of $208.9 million and an enterprise value of just $66.3 million after subtracting $145.6 million in cash. This valuation structure implies the market assigns minimal value to the underlying platform and pipeline, pricing the company near net cash despite profitability and multiple catalysts.

The EV/Revenue multiple of 0.91x compares favorably to clinical-stage biotech peers: iTeos (ITOS) trades at effectively infinite revenue multiple, Arcus at 11.08x, BeiGene (BGNE) at 7.05x, and Coherus (CHRS) at 6.18x. Even adjusting for milestone-driven revenue volatility, Compugen's multiple suggests significant undervaluation relative to peers with similar-stage pipelines. Either the market is pricing in extreme execution risk, or the partnership model is being valued as a one-time windfall rather than a sustainable business.

The P/E ratio of 5.79x appears low because 2025 earnings were milestone-driven rather than recurring. However, the P/S ratio of 2.87x still trades at a 50-70% discount to peers, suggesting the market doubts the sustainability of revenue generation. This creates an asymmetry: if Compugen delivers positive MAIA-ovarian data or the TIGIT class is validated, the multiple could re-rate toward peer averages, implying 100-200% upside from current levels.

Balance sheet strength provides a valuation floor. With $145.6 million in cash, no debt, and a quarterly burn rate that turned positive in 2025, the company has over four years of runway. The enterprise value of $66.3 million represents less than half of one year's peak milestone potential ($195 million) and a fraction of the $758 million GS-0321 milestone package. Even in a downside scenario where programs fail, the cash position provides downside protection that many cash-burning biotechs lack.

The $195 million in remaining milestones from AstraZeneca and up to $758 million from Gilead represent embedded optionality not reflected in the current valuation. While risk-adjusted values are lower, the sheer magnitude of potential payments creates a favorable risk/reward skew. Investors are getting a validated discovery platform and multiple clinical programs for an enterprise value that would barely cover the cost of a single Phase III trial, suggesting the market has yet to recognize the capital efficiency of Compugen's model.

Conclusion: A Capital-Efficient Platform at an Inflection Point

Compugen has engineered a rare biotech transformation, converting computational discovery capabilities into near-term profitability and a four-year cash runway without shareholder dilution. The partnership model, validated by AstraZeneca's $65 million royalty payment and Gilead's $90 million in upfront milestones, demonstrates that Unigen can generate assets worthy of major pharma investment, de-risking the platform while preserving long-term upside.

The investment thesis hinges on two critical variables: the Q1 2027 MAIA-ovarian interim analysis that could establish COM701 as a first-in-class maintenance therapy, and the 2026 Arcus/Gilead Phase III data that may validate the Fc-reduced TIGIT class and re-rate COM902. Success in either program would validate Compugen's differentiated approach to antibody design and target selection, likely triggering multiple expansion toward peer-group levels and unlocking the $953 million in remaining milestones.

Trading at 0.91x EV/Revenue with $145.6 million in cash and no debt, the valuation appears to price in significant execution risk while ignoring the platform's validated ability to generate partner-quality assets. For investors willing to accept the concentration risk and clinical trial uncertainties, Compugen offers an asymmetric risk/reward profile: downside protection from cash and near-term milestones, with upside optionality from a differentiated pipeline in a rapidly evolving IO landscape where safety and novel mechanisms are becoming paramount. The story that began in 1993 as a computational biology experiment has matured into a self-funding biotech platform, and the market has yet to price this inflection.